Cell therapy for end-stage liver disease:Current state and clinical challenge  

作　　者：Lin Zhang Yuntian Deng Xue Bai Xiao Wei Yushuang Ren Shuang Chen Hongxin Deng 

机构地区：[1]Department of Biotherapy,Cancer Center and State Key Laboratory of Biotherapy,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China

出　　处：《Chinese Medical Journal》2024年第23期2808-2820,共13页中华医学杂志(英文版)

基　　金：supported by grants from the National Key R&D Program of China grant(No.2022YFA1105602);the technology Major Project in Sichuan Province of China(No.2022ZDZX0024);1.3.5 project for disciplines of excellence,West China Hospital,Sichuan University(No.ZYGD23023).

摘　　要：Liver disease involves a complex interplay of pathological processes,including inflammation,hepatocyte necrosis,and fibrosis.End-stage liver disease(ESLD),such as liver failure and decompensated cirrhosis,has a high mortality rate,and liver transplantation is the only effective treatment.However,to overcome problems such as the shortage of donor livers and complications related to immunosuppression,there is an urgent need for new treatment strategies that need to be developed for patients with ESLD.For instance,hepatocytes derived from donor livers or stem cells can be engrafted and multiplied in the liver,substituting the host hepatocytes and rebuilding the liver parenchyma.Stem cell therapy,especially mesenchymal stem cell therapy,has been widely proved to restore liver function and alleviate liver injury in patients with severe liver disease,which has contributed to the clinical application of cell therapy.In this review,we discussed the types of cells used to treat ESLD and their therapeutic mechanisms.We also summarized the progress of clinical trials around the world and provided a perspective on cell therapy.

关 键 词：Cell therapy End-stage liver disease Cell transplantation Liver regeneration FIBROSIS IMMUNOREGULATION 

分 类 号：R57[医药卫生—消化系统]